- 1.
- 2.
- 3.
Grech
V, Balzan
M, Distefano
S. Paediatric wheezy admissions at and around school holiday periods. Malta Med J
2004;16:23–6.
- 4.
Kimes
D, Levine
E, Timmins
S, Weiss
SR, Bollinger
ME, Blaisdell
C. Temporal dynamics of emergency department and hospital admissions of pediatric asthmatics. Environ Res
2004;94:7–17. 10.1016/S0013-9351(03)00046-X [
PubMed: 14643281] [
CrossRef]
- 5.
Kimbell-Dunn
M, Pearce
N, Beasley
R. Seasonal variation in asthma hospitalizations and death rates in New Zealand. Respirology
2000;5:241–6. 10.1046/j.1440-1843.2000.00255.x [
PubMed: 11022986] [
CrossRef]
- 6.
Gergen
PJ, Mitchell
H, Lynn
H. Understanding the seasonal pattern of childhood asthma: results from the National Cooperative Inner-City Asthma Study (NCICAS). J Pediatr
2002;141:631–6. 10.1067/mpd.2002.127510 [
PubMed: 12410190] [
CrossRef]
- 7.
Harju
T, Keistinen
T, Tuuponen
T, Kivelä
SL. Seasonal variation in childhood asthma hospitalisations in Finland, 1972–92. Eur J Pediatr
1997;156:436–9. 10.1007/s004310050632 [
PubMed: 9208236] [
CrossRef]
- 8.
Julious
SA, Osman
LM, Jiwa
M. Increases in asthma hospital admissions associated with the end of the summer vacation for school-age children with asthma in two cities from England and Scotland. Public Health
2007;121:482–4. 10.1016/j.puhe.2006.11.011 [
PubMed: 17276466] [
CrossRef]
- 9.
Silverman
RA, Stevenson
L, Hastings
HM. Age-related seasonal patterns of emergency department visits for acute asthma in an urban environment. Ann Emerg Med
2003;42:577–86. 10.1067/S0196-0644(03)00410-4 [
PubMed: 14520329] [
CrossRef]
- 10.
Fleming
DM, Cross
KW, Sunderland
R, Ross
AM. Comparison of the seasonal patterns of asthma identified in general practitioner episodes, hospital admissions, and deaths. Thorax
2000;55:662–5. 10.1136/thorax.55.8.662 [
PMC free article: PMC1745832] [
PubMed: 10899242] [
CrossRef]
- 11.
Murray
CS, Poletti
G, Kebadze
T, Morris
J, Woodcock
A, Johnston
SL, Custovic
A. Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children. Thorax
2006;61:376–82. 10.1136/thx.2005.042523 [
PMC free article: PMC2111190] [
PubMed: 16384881] [
CrossRef]
- 12.
Gulliford
MC, van Staa
T, McDermott
L, Dregan
A, McCann
G, Ashworth
M, et al.
Cluster randomised trial in the General Practice Research Database: 1. Electronic decision support to reduce antibiotic prescribing in primary care (eCRT study). Trials
2011;12:115. 10.1186/1745-6215-12-115 [
PMC free article: PMC3101122] [
PubMed: 21569237] [
CrossRef]
- 13.
Julious
SA, Campbell
MJ, Bianchi
SM, Murray-Thomas
T. Seasonality of medical contacts in school-aged children with asthma: association with school holidays. Public Health
2011;125:769–76. 10.1016/j.puhe.2011.08.005 [
PubMed: 22036686] [
CrossRef]
- 14.
Curtis
L. Unit Costs of Health and Social Care 2011. Canterbury: PSSRU, University of Kent; 2011.
- 15.
Department of Health. 2010–11 Reference Costs Publication. London: Department of Health; 2011.
- 16.
- 17.
Horspool
MJ, Julious
SA, Boote
J, Bradburn
MJ, Cooper
CL, Davis
S, et al.
Preventing and lessening exacerbations of asthma in school-age children associated with a new term (PLEASANT): study protocol for a cluster randomised control trial. Trials
2013;14:297. 10.1186/1745-6215-14-297 [
PMC free article: PMC4016495] [
PubMed: 24041259] [
CrossRef]
- 18.
Williams
T, van Staa
T, Puri
S, Eaton
S. Recent advances in the utility and use of the General Practice Research Database as an example of a UK primary care data resource. Ther Adv Drug Saf
2012;3:89–99. 10.1177/2042098611435911 [
PMC free article: PMC4110844] [
PubMed: 25083228] [
CrossRef]
- 19.
Tate
AR, Beloff
N, Al-Radwan
B, Wickson
J, Puri
S, Williams
T, et al.
Exploiting the potential of large databases of electronic health records for research using rapid search algorithms and an intuitive query interface. J Am Med Inform Assoc
2014;21:292–8. 10.1136/amiajnl-2013-001847 [
PMC free article: PMC3932457] [
PubMed: 24272162] [
CrossRef]
- 20.
Horspool
MJ, Julious
SA, Mooney
C, May
R, Sully
B, Smithson
WH. Preventing and Lessening Exacerbations of Asthma in School-aged children Associated with a New Term (PLEASANT): recruiting primary care research sites – the PLEASANT experience. NPJ Prim Care Respir Med
2015;25:15066. 10.1038/npjpcrm.2015.66 [
PMC free article: PMC4642399] [
PubMed: 26562491] [
CrossRef]
- 21.
Julious
SA, Horspool
MJ, Boote
J. PLEASANT Trial: 2nd Consultation Event with Children with Asthma and their Parents. ScHARR Report Series No: 28. Sheffield: University of Sheffield; 2012.
- 22.
Hatfield
I, Julious
SA, Davis
S, Horspool
MJ, Norman
P, Mooney
C. An Assessment of the Resources used by General Practices in the Intervention Arm of the PLEASANT Study in Sending out the Intervention. ScHARR Report Series No: 30. Sheffield: School of Health and Related Research (ScHARR), University of Sheffield; 2015.
- 23.
Great Britain. Data Protection Act 1998. London: The Stationery Office; 1998.
- 24.
Ukoumunne
OC, Gulliford
MC, Chinn
S, Sterne
JA, Burney
PG. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technol Assess
1999;3(5). [
PubMed: 10982317]
- 25.
- 26.
- 27.
Simpson
RM, Julious
SA, Mooney
C, Norman
P. PLEASANT TRIAL: 3rd Consultation Event with Children with Asthma and their Parents. ScHARR Report Series No: 32. Sheffield: School of Health and Related Research (ScHARR), University of Sheffield; 2015.
- 28.
Boote
J, Julious
S, Horspool
M, Elphick
H, Smithson
WH, Norman
P. PPI in the PLEASANT trial: involving children with asthma and their parents in designing an intervention for a randomised controlled trial based within primary care. Prim Health Care Res Dev
2016;17:536–48. 10.1017/S1463423616000025 [
PubMed: 26856306] [
CrossRef]
- 29.
Wu
S, Crespi
CM, Wong
WK. Comparison of methods for estimating the intraclass correlation coefficient for binary responses in cancer prevention cluster randomized trials. Contemp Clin Trials
2012;33:869–80. 10.1016/j.cct.2012.05.004 [
PMC free article: PMC3426610] [
PubMed: 22627076] [
CrossRef]
- 30.
Curtis
L. Unit Costs of Health and Social Care 2014. Canterbury: PSSRU, University of Kent; 2014.
- 31.
National Institute for Health Research Clinical Research Network. Clinical Research Network Industry Costing Template. London: National Institute for Health Research Clinical Research Network; 2015.
- 32.
Department of Health. National Schedule of Reference Costs 2013–14: NHS Trusts and NHS Foundation Trusts. London: Department of Health; 2014.
- 33.
Joint Formulary Committee. British National Formulary for Children August 2015. London: BMJ Group and Pharmaceutical Press; 2015. URL:
www.medicinescomplete.com (accessed 1 August 2016).
- 34.
DocMail. DocMail Online Price List. 2015. URL:
www.docmail.co.uk (accessed 25 July 2016).
- 35.
National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. London: NICE; 2013. [
PubMed: 27905712]
- 36.
Willems
DC, Joore
MA, Hendriks
JJ, Wouters
EF, Severens
JL. Cost-effectiveness of a nurse-led telemonitoring intervention based on peak expiratory flow measurements in asthmatics: results of a randomised controlled trial. Cost Eff Resour Alloc
2007;5:10. 10.1186/1478-7547-5-10 [
PMC free article: PMC2000864] [
PubMed: 17662113] [
CrossRef]
- 37.
Lloyd
A, Price
D, Brown
R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J
2007;16:22–7. 10.3132/pcrj.2007.00002 [
PMC free article: PMC6634181] [
PubMed: 17297523] [
CrossRef]
- 38.
Briggs
AH, Bousquet
J, Wallace
MV, Busse
WW, Clark
TJ, Pedersen
SE, Bateman
ED, GOAL Investigators Group. Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. Allergy
2006;61:531–6. 10.1111/j.1398-9995.2006.01038.x [
PubMed: 16629780] [
CrossRef]
- 39.
Hunter
RM, Baio
G, Butt
T, Morris
S, Round
J, Freemantle
N. An educational review of the statistical issues in analysing utility data for cost-utility analysis. PharmacoEconomics
2015;33:355–66. 10.1007/s40273-014-0247-6 [
PubMed: 25595871] [
CrossRef]
- 40.
van Asselt
AD, van Mastrigt
GA, Dirksen
CD, Arntz
A, Severens
JL, Kessels
AG. How to deal with cost differences at baseline. PharmacoEconomics
2009;27:519–28. 10.2165/00019053-200927060-00007 [
PubMed: 19640014] [
CrossRef]
- 41.
Efron
B. Better bootstrap confidence intervals. J Am Stat Assoc
1987;82:171–85. 10.1080/01621459.1987.10478410 [
CrossRef]
- 42.
Oehlert
GW. A note on the delta method. Am Stat
1992;46:1992.
- 43.
Yong
YV, Shafie
AA. Economic evaluation of enhanced asthma management: a systematic review. Value Health
2013;16:A377. 10.1016/j.jval.2013.08.312 [
CrossRef]
- 44.
Stevens
K. Valuation of the Child Health Utility Index 9D (CHU9D). Discussion paper number 10/07. Sheffield: University of Sheffield; 2010.
- 45.
Papaioannou
D, Brazier
JE, Paisley
S. The Identification, Review and Synthesis of Health State Utility Values from the Literature. Sheffield: University of Sheffield; 2011.
- 46.
Powell
C, Kolamunnage-Dona
R, Lowe
J, Boland
A, Petrou
S, Doull
I, et al.
MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo-controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children. Health Technol Assess
2013(17). [
PMC free article: PMC4781380] [
PubMed: 24144222]
- 47.
Price
D, Musgrave
S, Wilson
E, Sims
E, Shepstone
L, Blyth
A, et al.
A pragmatic single-blind randomised controlled trial and economic evaluation of the use of leukotriene receptor antagonists in primary care at steps 2 and 3 of the national asthma guidelines (ELEVATE study). Health Technol Assess
2011(15). [
PubMed: 21554855]
- 48.
Brusselle
G, Michils
A, Louis
R, Dupont
L, Van de Maele
B, Delobbe
A, et al.
“Real-life” effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med
2009;103:1633–42. 10.1016/j.rmed.2009.06.014 [
PubMed: 19619998] [
CrossRef]
- 49.
Chiou
CF, Weaver
MR, Bell
MA, Lee
TA, Krieger
JW. Development of the multi-attribute Pediatric Asthma Health Outcome Measure (PAHOM). Int J Qual Health Care
2005;17:23–30. 10.1093/intqhc/mzh086 [
PubMed: 15668307] [
CrossRef]
- 50.
Mittmann
N, Trakas
K, Risebrough
N, Liu
BA. Utility scores for chronic conditions in a community-dwelling population. PharmacoEconomics
1999;15:369–76. 10.2165/00019053-199915040-00004 [
PubMed: 10537955] [
CrossRef]
- 51.
Juniper
EF, Guyatt
GH, Feeny
DH, Griffith
LE, Ferrie
PJ. Minimum skills required by children to complete health-related quality of life instruments for asthma: comparison of measurement properties. Eur Respir J
1997;10:2285–94. 10.1183/09031936.97.10102285 [
PubMed: 9387955] [
CrossRef]
- 52.
Norman
G, Faria
R, Paton
F, Llewellyn
A, Fox
D, Palmer
S, et al.
Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess
2013;17(52). 10.3310/hta17520 [
PMC free article: PMC4781123] [
PubMed: 24267198] [
CrossRef]
- 53.
Doull
I, Price
D, Thomas
M, Hawkins
N, Stamuli
E, Tabberer
M, et al.
Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma. Curr Med Res Opin
2007;23:1147–59. 10.1185/030079907X187982 [
PubMed: 17519082] [
CrossRef]
- 54.
Rodríguez-Martínez
CE, Sossa-Briceño
MP, Castro-Rodriguez
JA. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma. J Asthma
2013;50:410–18. 10.3109/02770903.2013.767909 [
PubMed: 23356720] [
CrossRef]
- 55.
Carroll
AE, Downs
SM. Improving decision analyses: parent preferences (utility values) for pediatric health outcomes. J Pediatr
2009;155:21–5.e1–5. [
PubMed: 19394030]
- 56.
Brown
R, Turk
F, Dale
P, Bousquet
J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy
2007;62:149–53. 10.1111/j.1398-9995.2006.01310.x [
PubMed: 17298423] [
CrossRef]
- 57.
Gerald
JK, Grad
R, Bailey
WC, Gerald
LB. Cost-effectiveness of school-based asthma screening in an urban setting. J Allergy Clin Immunol
2010;125:643–50.e1–650.e12. [
PubMed: 20226298]
- 58.
Brazier
J, Ratcliffe
J, Solomon
J, Tsuchiya
A. Measuring and valuing health benefits for economic valuation. PharmacoEconomics
2007;25:353. 10.2165/00019053-200725040-00007 [
CrossRef]
- 59.
Cheung
K, Oemar
M, Oppe
M, Rabin
R. User Guide: BASIC Information on How to Use EQ-5D. Rotterdam: EuroQol Research Foundation; 2009.
- 60.
Brazier
JE, Rowen
D. Alternatives to EQ-5D for Generating Health State Utility Values. Sheffield: University of Sheffield; 2011.
- 61.
Steuten
L, Palmer
S, Vrijhoef
B, van Merode
F, Spreeuwenberg
C, Severens
H. Cost-utility of a disease management program for patients with asthma. Int J Technol Assess Health Care
2007;23:184–91. 10.1017/S0266462307070298 [
PubMed: 17493304] [
CrossRef]
- 62.
Tsuchiya
A, Brazier
JE, McColl
E, Parkin
D. Deriving Preference-Based Condition-Specific Instruments: Converting AQLQ into EQ-5D Indices. Sheffield: University of Sheffield; 2002.
- 63.
Ayres
JG, Higgins
B, Chilvers
ER, Ayre
G, Blogg
M, Fox
H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy
2004;59:701–8. 10.1111/j.1398-9995.2004.00533.x [
PubMed: 15180756] [
CrossRef]
- 64.
Eccles
M, Grimshaw
J, Steen
N, Parkin
D, Purves
I, McColl
E, Rousseau
N. The design and analysis of a randomized controlled trial to evaluate computerized decision support in primary care: the COGENT study. Fam Pract
2000;17:180–6. 10.1093/fampra/17.2.180 [
PubMed: 10758083] [
CrossRef]
- 65.
Price
D, Brown
RE, Lloyd
A. Burden of poorly controlled asthma for patients and society in the UK. Prim Care Respir J
2004;13:113.
- 66.
Bateman
ED, Boushey
HA, Bousquet
J, Busse
WW, Clark
TJ, Pauwels
RA, Pedersen
SE, GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med
2004;170:836–44. 10.1164/rccm.200401-033OC [
PubMed: 15256389] [
CrossRef]
